Intended Audience:  Healthcare Professionals including OB/GYNs, Advance Practice Providers specializing in Women's Health (NPs, PAs, APRNs, CNMs, and RNs); Primary Care Physicians including Family Medicine and Internal Medicine; Pharmacist

Bayer TA Rationale for Educational Support:

• Expand awareness of the role of the hypothalamic KNDy system on vasomotor symptoms, sleep disorders, and mood disturbances.
• Discuss novel and emerging therapies for menopause symptom management targeting the KNDy system to increase the understanding of their safety and tolerability.
• Provide guidance on the identification, counseling, and management of women as they enter the menopausal transition.
• Impact of untreated menopause symptoms on chronic diseases (e.g., cardiovascular disease)

Preferred Format:

• Enduring
• Downloadable slides
• Incorporation of social media outreach (YouTube, Facebook, Spotify, Instagram, LinkedIn, X)
• Podcast
• Live Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:

•Needs assessment
• Educational design and rationale for selection (where applicable)
•Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:
• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

Publication References

1.Rance NE, Dacks PA, Mittleman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34:211. 
2.Koysombat K, McGown P, Nyunt S, Abbara A, Dhillo WS. New advances in menopause symptom management. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101774. doi: 10.1016/j.beem.2023.101774. Epub 2023 Apr 11. PMID: 37076317. 
3.Pertynska-Marczewska M, Pertynski T. Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape. Eur J Obstet Gynecol Reprod Biol. 2024 Nov;302:141-148. doi: 10.1016/j.ejogrb.2024.09.013. Epub 2024 Sep 12. PMID: 39270577. 
4.Menegaz de Almeida A, Oliveira P, Lopes L, Leite M, Morbach V, Alves Kelly F, Barros Í, Aquino de Moraes FC, Prevedello A. Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. Obstet Gynecol. 2025 Jan 2. doi: 10.1097/AOG.0000000000005812. Epub ahead of print. PMID: 39746208. 
5.Pinkerton JV, Simon J, Panay N, Seitz C, Parke S, Caetano C, Mellinger U, Haseli Mashhadi N, Haberland C, Atanackovic G, Holz C, Mao G, Morrison M, Nisius S, Schaefers M, Zuurman L. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause. Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3. PMID: 38564691. 
6.Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024 Aug 22;332(16):1343–54. doi: 10.1001/jama.2024.14618. Epub ahead of print. PMID: 39172446; PMCID: PMC11342219. 
7.Schulz SI, Schultze-Mosgau MH, Engelen A, Singh N, Pawsey S, Francke K, Lock R, Rottmann A. Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation. Eur J Drug Metab Pharmacokinet. 2024 Dec 24. doi: 10.1007/s13318-024-00930-3. Epub ahead of print. PMID: 39719488. 
8.El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020 Dec 22;142(25):e506-e532. doi: 10.1161/CIR.0000000000000912. Epub 2020 Nov 30. PMID: 33251828. 
9.Ryu KJ, Park H, Park JS, Lee YW, Kim SY, Kim H, Jeong Y, Kim YJ, Yi KW, Shin JH, Hur JY, Kim T. Vasomotor Symptoms: More Than Temporary Menopausal Symptoms. J Menopausal Med. 2020 Dec;26(3):147-153. doi: 10.6118/jmm.20030. PMID: 33423402; PMCID: PMC7797223. 
10.Thurston RC, Maki P, Chang Y, Wu M, Aizenstein HJ, Derby CA, Karikari TK. Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers. Am J Obstet Gynecol. 2024 Mar;230(3):342.e1-342.e8. doi: 10.1016/j.ajog.2023.11.002. Epub 2023 Nov 7. PMID: 37939982; PMCID: PMC10939914. 
11.Thurston RC. Vasomotor symptoms and cardiovascular health: findings from the SWAN and the MsHeart/MsBrain studies. Climacteric. 2024 Feb;27(1):75-80. doi: 10.1080/13697137.2023.2196001. Epub 2023 Aug 14. PMID: 37577812; PMCID: PMC10843629.